BOSTON & PERTH, Australia--(BUSINESS WIRE)--Feb. 10, 2006--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that its Retisert(TM) product licensed to Bausch & Lomb, will be co-promoted in the United States by Novartis Ophthalmics, a business unit of Novartis Pharmaceutical Corp. Retisert(TM), developed by pSivida, is the world’s first intravitreal drug implant for the treatment of chronic noninfectious posterior segment uveitis, a sight threatening condition that affects an estimated 175,000 people in the United States and an estimated 800,000 people worldwide.
